malformations associated with methimazole use compared with no antithyroid drug use (17.1 cases per 1,000 live births) is almost double that of propylthiouracil (8.8 cases per 1,000 live births), which is in contrast to a similar study from Denmark 7 showing malformations in 9.1% of pregnancies after methimazole use and in 8% after propyl thiouracil use. This difference between the two studies could be attributed to the fact that the follow-up of the children in the current study 5 was shorter than that of the Denmark study (until age 1 year versus 2 years, respectively). Less severe defects, as seen after propylthiouracil use, are likely to be identified at a later stage than more severe defects seen after methimazole use. This observation is also why studies with a longer child follow-up show smaller differences in the risk of congenital malformations between methimazole and propylthiouracil.
Women who switched from methimazole to propylthiouracil use before conception had a similar risk of congenital malformations (OR 1.06, 95% CI 0.79-1.42, P = 0.71) to those who continued to use methimazole during pregnancy 5 . Interestingly, this included women who switched antithyroid drug treatment ~3 months before conception. These findings suggest that the currently advised strategy to switch from methimazole to propylthiouracil during early pregnancy, or even 3 months before pregnancy, has no beneficial effect, but this new finding needs to be replicated in future studies. This study illustrates that a timely switch from methimazole to propylthiouracil is not always feasible as most pregnancies in developed countries are unplanned; for the majority of women the switch took place during the (early) teratogenic period. Although methimazole is the drug of choice outside of pregnancy, propylthiouracil treatment could be beneficial for women who are unwilling to undergo permanent treatment or who are unlikely to plan a pregnancy.
Perhaps the most interesting and novel findings of the current study 5 are those showing dose-dependent effects. For propylthiouracil use, neither the duration of treatment nor the cumulative dosage was associated with congenital malformations. Although this result could suggest that there is a very low teratogenicity threshold, it is an unexpected finding and even offers evidence against a true causal effect of propylthiouracil on fetal anomalies. For methimazole, a longer duration of 
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treatment (>7 weeks) was associated with an up to 68% (OR 1.68, 95% CI 0.91-3.11, P = 0.10) higher risk of malformations, although this did not reach statistical significance due to a lack of power. However, a higher cumulative methimazole dosage (>495 mg) was associated with an 87% higher risk of congenital malformations (OR 1.87, 95% CI 1.06-3.30, P = 0.03). This result is in line with the concept of avoiding a 'block-and-replace' strategy and provides evidence in favour of a cessation trial in women who are biochemically controlled with low-dose treatment before pregnancy.
The current post-marketing study is the best available evidence available in this field due to the low prevalence of Graves disease during pregnancy. Further studies are necessary to unravel effect thresholds according to the cumulative dosage, duration of treatment and timing of antithyroid drug use, as well as studies on the feasibility of alternative treatments for gestational Graves disease such as high-dose potassium iodine 8, 9 . In the metastatic setting, in which the anti-VEGF therapy bevacizumab first gained accelerated approval in 2008, overall response rates were positive, but conflicting reports on progression-free survival and overall survival benefit led to the reversal of this approval in 2010. The reasons for the discrepancies in patient outcomes and lack of overall benefit are multifactorial and include what some researchers speculate are differences in study populations and angiogenesis resistance mechanisms.
One such mechanism has been investigated in detail. Incio et al. 1 hypothesized that obesity promotes resistance to anti-VEGF therapy in breast cancer via the overproduction of alternative angiogenic factors. To test this notion, the authors performed a subanalysis of a phase II clinical trial evaluating bevacizumab in the neoadjuvant setting. Results showed that patients with excess weight (BMI >25 kg/m 2 ) present with larger and more hypoxic tumours than patients with BMI <25 kg/m 2 . Patients who were overweight also had increased circulating concentrations of IL-6 and fibroblast growth factor 2 (FGF2) and expression of these factors in tumours was localized in close juxtaposition to adipocyte-rich areas 1 . In order to evaluate whether obesity can alter the response to anti-VEGF therapy in breast cancer, the authors fed two syngeneic murine orthotopic models -reflecting either oestrogen receptor-positive breast cancer (E0771) or triple-negative breast cancer (MCaIV) -high-fat and low-fat diets to generate obese and lean mice. In the oestrogen receptor-positive breast cancer setting, treatment with B20, an anti-VEGF antibody, was more effective at inhibiting tumour growth in lean E0771 mice than in obese E0771 mice. Tumours have their own blood supply for nutrition and oxygenation and typically induce these blood vessels by secretion of angiogenic factors including VEGF. Tumours from obese E0771 mice had decreased blood vessel density and, similarly to what was observed in humans, higher levels of IL-6 than lean mice. Of note, the authors identified the source of IL-6 as adipocytes and infiltrating immune cells. In addition to increased IL-6, tumours from obese E0771 mice had increased expression of carbonic anhydrase 9 (CAIX) and glucose transporter 1 (two markers for hypoxia) compared with tumours from lean mice. This increase in hypoxia markers, which identify the oxygen-deprived state of the tumour, was associated with an increase in the number of cancer-associated adipocytes, which are fat cells that associate with or surround the tumour. Interestingly, Incio and colleagues found that IL-6 expression was localized in adipocyte-rich regions of E0771 tumours and colocalized with the expression of hypoxia markers 1 .
The authors then performed IL-6 inhibition using an anti-IL-6 antibody in combination with B20, which reduced tumour growth and metastasis in obese mice to rates similar to those observed for lean mice receiving just B20. Importantly, IL-6 blockade did not improve the response to B20 in the lean setting, suggesting that IL-6 has an important role in tumour progression, but only in the context of obesity and anti-VEGF therapy 1 . In obese, but not lean, mice, the combination therapy also increased tumour blood vessel density, decreased the expression of CAIX by ~60% and diminished the infiltration of immune cells 1 .
The evidence for an association of obesity with triple-negative breast cancer is not consistent. While most studies have reported that obesity increases the risk of premenopausal triple-negative breast cancer, results for postmenopausal triple-negative breast cancer are inconclusive 3 . It is therefore interesting that in MCaIV mice the authors discovered that FGF2, but not IL-6, was strongly associated with obesity 1 . As was the case with IL-6 in the oestrogen receptor-positive breast cancer setting, the authors found FGF2 to be highly expressed in adipocyte-rich areas, but they also observed FGF2 in activated cancer-associated fibroblasts, which are cells that surround the tumour and promote tumour growth by secreting angiogenic factors including VEGF. Tumours from obese MCaIV mice were less vascularized, more hypoxic and had increased resistance to B20 than tumours from lean mice. Of note, FGF receptor blockade improved tumour responsiveness to anti-VEGF therapy in obese mice 1 . The authors then treated MCaIV mice with B20 in combination with metformin, which reduces expression of FGF2. The results showed that metformin reduced expression of FGF2 in tumours from B20-treated obese MCaIV mice, inhibited FGF2 downstream signalling pathways (AKT, S6, ERK and signal transducer and activator of transcription 3 (STAT3)), reduced vessel density and resensitized tumours to anti-VEGF treatment 1 . One limiting factor in the generalizability of their findings is that Incio and colleagues did not investigate obesity-related human epidermal growth factor receptor 2 (HER2)-positive breast cancer. In HER2-positive breast cancer, activation of the IL-6 feedback loop expands the cancer stem cell population resulting in resistance to trastuzumab 4 . A phase III trial of docetaxel and trastuzumab did not show any significant differences in survival with the addition of bevacizumab 5 . It would have been interesting to evaluate whether IL-6 or FGF2 has a role in HER2-positive breast cancer or if another mechanism entirely was pertinent. It is conceivable that similar blockade of IL-6 in combination with anti-VEGF therapy would restore tumour sensitivity in HER2-positive breast cancer.
Overall, the findings by Incio and colleagues 1 point the way for a comeback for anti-VEGF therapy in breast cancer, specifically as it pertains to obesity-related breast cancer. The results provide valuable steps towards using a precision medicine approach in future clinical trial design. They also provide additional reasons for maintaining a healthy weight not only for breast cancer prevention, but also for better cancer management and survival.
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